WO2002026775A3 - Compositions and methods for regulating apoptosis - Google Patents

Compositions and methods for regulating apoptosis Download PDF

Info

Publication number
WO2002026775A3
WO2002026775A3 PCT/US2001/030567 US0130567W WO0226775A3 WO 2002026775 A3 WO2002026775 A3 WO 2002026775A3 US 0130567 W US0130567 W US 0130567W WO 0226775 A3 WO0226775 A3 WO 0226775A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
peptides
compositions
apoptosis
iap
Prior art date
Application number
PCT/US2001/030567
Other languages
French (fr)
Other versions
WO2002026775A2 (en
Inventor
Yigong Shi
Original Assignee
Univ Princeton
Yigong Shi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton, Yigong Shi filed Critical Univ Princeton
Priority to AU2001293189A priority Critical patent/AU2001293189A1/en
Publication of WO2002026775A2 publication Critical patent/WO2002026775A2/en
Publication of WO2002026775A3 publication Critical patent/WO2002026775A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptides and peptidomimetics capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The peptides and mimetics are based on the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptides and peptidomimetics for therapeutic purposes and for rational drug design.
PCT/US2001/030567 2000-09-29 2001-09-28 Compositions and methods for regulating apoptosis WO2002026775A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001293189A AU2001293189A1 (en) 2000-09-29 2001-09-28 Compositions and methods for regulating apoptosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/236,574 2000-09-29
US25683000P 2000-12-20 2000-12-20
US60/256,830 2000-12-20

Publications (2)

Publication Number Publication Date
WO2002026775A2 WO2002026775A2 (en) 2002-04-04
WO2002026775A3 true WO2002026775A3 (en) 2003-01-23

Family

ID=34806773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030567 WO2002026775A2 (en) 2000-09-29 2001-09-28 Compositions and methods for regulating apoptosis

Country Status (2)

Country Link
AU (1) AU2001293189A1 (en)
WO (1) WO2002026775A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030959A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
MXPA03010762A (en) * 2001-05-31 2005-03-07 Univ Princeton Iap binding peptides and assays for identifying compounds that bind iap.
US20050222017A1 (en) * 2002-02-19 2005-10-06 Klaus Heese Apoptosis promoter and inhibitor interacting with cgi-94, and method of screening the same
EP1354952A1 (en) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354953A1 (en) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) * 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1378515A1 (en) * 2002-07-01 2004-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inducing apoptosis in tumor cells
AU2003265276A1 (en) * 2002-07-15 2004-02-02 The Trustees Of Princeton University Iap binding compounds
JP4315249B2 (en) * 2003-02-07 2009-08-19 ジェネンテック・インコーポレーテッド Compositions and methods for promoting apoptosis
CN1926118A (en) 2004-03-01 2007-03-07 德克萨斯大学董事会 Dimeric small molecule potentiators of apoptosis
CA2558615C (en) 2004-03-23 2013-10-29 Genentech, Inc. Azabicyclo-octane inhibitors of iap
CN101035802A (en) 2004-07-02 2007-09-12 健泰科生物技术公司 Inhibitors of IAP
ES2475207T3 (en) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation IAP binding compounds
EA019420B1 (en) 2004-12-20 2014-03-31 Дженентех, Инк. Pyrrolidine inhibitors of iap (apoptosis inhibitors)
BRPI0607988A2 (en) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals compound, pharmaceutical composition, and method for inducing apoptosis in a cell
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009512719A (en) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド IAPBIR domain binding compound
CN101374829A (en) 2005-12-19 2009-02-25 健泰科生物技术公司 Inhibitors of IAP
TWI543988B (en) 2006-03-16 2016-08-01 科學製藥股份有限公司 Iap bir domain binding compounds
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
CL2007002166A1 (en) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer.
AU2007337104A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of IAP
AR066348A1 (en) 2007-04-30 2009-08-12 Genentech Inc IAP INHIBITORS
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2567544C2 (en) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir domain iap binding compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002030959A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002030959A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A M VERHAGEN ET AL.: "Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins", CELL, vol. 102, 7 July 2000 (2000-07-07), CELL PRESS, CAMBRIDGE, NA., US, pages 43 - 53, XP002175397, ISSN: 0092-8674 *
C DU ET AL.: "Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition", CELL, vol. 102, 7 July 2000 (2000-07-07), CELL PRESS, CAMBRIDGE, NA., US, pages 33 - 42, XP002175396, ISSN: 0092-8674 *
J CHAI ET AL.: "Structural and biochemical basis of apoptotic activation by Smac/DIABLO", NATURE., vol. 406, 24 August 2000 (2000-08-24), MACMILLAN MAGAZINES., US, pages 855 - 862, XP002200489, ISSN: 0028-0836 *
Y SHI: "A conserved tetrapeptide motif; potentiating apoptosis through IAP binding", CELL DEATH AND DIFFERENTIATION., vol. 9, February 2002 (2002-02-01) - 1903, EDWARD ARNOLD, OXFORD., GB, pages 93 - 95, XP002204122, ISSN: 1350-9047 *

Also Published As

Publication number Publication date
AU2001293189A1 (en) 2002-04-08
WO2002026775A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
WO2002026775A3 (en) Compositions and methods for regulating apoptosis
AU2003265276A1 (en) Iap binding compounds
WO2006091972A3 (en) Dimeric iap inhibitors
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU6604798A (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
GB9318207D0 (en) Improvements in or relating to organic compounds
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2002096930A3 (en) Iap binding peptides and assays for identifying compounds that bind iap
EP1481059A4 (en) Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
EP1983059A3 (en) Reaction mixtures for producing dipeptides
WO2002079408A3 (en) Short bioactive peptides and methods for their use
WO2006113898A3 (en) Pif tetrapeptides
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
WO2003074546A3 (en) Streptavidin-binding peptide
WO2001085777A3 (en) Therapeutic pore-forming peptides
ATE402714T1 (en) STABILIZATION OF PHARMACEUTICAL EPO FORMULATIONS WITH SMALL PEPTIDES
WO2003031585A3 (en) Transmembrane serine protease 25
AU4218389A (en) Peptide compounds
ATE385805T1 (en) NEW PEPTIDES
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP